Alimera Sciences Inc (ALIM) is around the top of the Drug Manufacturers - Specialty & Generic industry according to InvestorsObserver. ALIM received an overall rating of 70, which means that it scores higher than 70 percent of all stocks. Alimera Sciences Inc also achieved a score of 95 in the Drug Manufacturers - Specialty & Generic industry, putting it above 95 percent of Drug Manufacturers - Specialty & Generic stocks. Drug Manufacturers - Specialty & Generic is ranked 139 out of the 148 industries.
ALIM has an Overall Score of 70. Find out what this means to you and get the rest of the rankings on ALIM!
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With Alimera Sciences Inc Stock Today?
Alimera Sciences Inc (ALIM) stock has risen 4.43% while the S&P 500 is down -0.04% as of 1:04 PM on Thursday, Aug 18. ALIM is up $0.30 from the previous closing price of $6.69 on volume of 7,468 shares. Over the past year the S&P 500 is down -2.90% while ALIM is up 31.14%. ALIM lost -$2.49 per share the over the last 12 months.
Click Here to get the full Stock Report for Alimera Sciences Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
